NCT04249375

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: University of British Columbia · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications. We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.

Detailed description

The specific objectives are to: 1. Implement a pilot pharmacogenomics program to test medication safety and effectiveness of antibiotics, analgesics and mental health medication to enhance prescribing decision-making. 2. Develop data collection forms to collect necessary patient information from the prescribing physicians. 3. Develop pharmacogenomics reports to return results to physicians, pharmacists, patients and their families. 4. Determine how the tests and results are perceived and utilized by physicians, pharmacists, patients and their families.

Conditions

• Adverse Drug Reaction (ADR)

Timeline

• Start date: 2020-02-20
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2020-01-30
• Last updated: 2024-12-05

Locations

2 sites across 1 country: Canada